Accelerate biotechnology

Article: Fairy godmother for research and development biopharmaceuticals

This week, the New Economy placed an article on the role of Batavia Biosciences in the research and development of biopharmaceuticals. Only five percent of candidate drugs currently make it through the initial R&D phase. With demand for novel biopharmaceuticals growing, Batavia Biosciences is helping organisations improve their development processes, accelerating production and ensuring high-quality…


Article: Making Research Count

Our CEO, Menzo Havenga has a hobby horse, a Clinical Development Board. It should ensure that high impact research will result in high quality products for patients. Currently in the Netherlands, the journey from paper to product is often heavily underestimated. A Clinical Development Board with experts from the early development stages to late development stages…


Article: Nanodisc offers chance better influenza vaccine

The Dutch newspaper, Leidsch Dagblad, published an article on the TTW-grant that the Leiden University has received to collaborate with private partners ZoBio, and Batavia Biosciences to propel SATIRN® technology, developed by Batavia Biosciences. The project aims to deliver, amongst others, a better influenza vaccine by use of this membrane protein formulation technology. Full article (in Dutch)


Video: Batavia Biosciences, your biopharmaceutical CDMO

Batavia Biosciences is a biopharmaceutical CDMO with an extensive track record in viral vaccine, viral vector, protein and antibody projects. We aim to significantly contribute to ease human suffering from disease by improving the success rate in the translation of candidate medicines from bench to clinic. We offer our technologies and in-depth knowhow to help…


Webinar: Latest Advancements in Production of Therapeutic Antibodies on E. coli

This webinar will give you insights in the possibilities that E. coli fermentation systems can offer for manufacturing of therapeutic antibodies, including antibody fragments. There will be special focus on our new fermentation technology, SCOPE®  technology: a system for a controlled regulation of protein expression yields in E. coli with a case study to showcase the latest technological advancements. Want…


Article: SIDUS® technology enables first clinical study with live attenuated Zika vaccine

Batavia Biosciences has, with its know-how developed under the SIDUS® technology, extensive expertise in house for the production and testing of viral vector based products, like lentiviral vectors, adenoviral vectors, AAV vectors and Measles vectors. This knowledge covers a broad area; from virus DNA construction and modification, to making research batches and clinical batches, including…